Sign inJoin waitlistJoin the waitlist

Helen Heslop

Program Director · Baylor College of Medicine

Credentials: · ·

History

Baylor College of Medicine
Present
Center for Cell & Gene Therapy · Baylor College of Medicine
Present
Dan L Duncan Comprehensive Cancer Center · Baylor College of Medicine
Present

Pediatrics
1990–1993
Pediatric Hematology Oncology
St Jude Children's Research Hospital
1988–1991
Baylor College of Medicine
1986–1990

Research

Inducible apoptosis as a safety switch for adoptive cell therapy
New England Journal of Medicine · 2011 · 1,281 citations
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Nature Medicine · 2008 · 992 citations
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
The Lancet · 1995 · Last of 8 authors · 976 citations

Malcolm Brenner
225 papers
Catherine Bollard
81 papers
Stephen Gottschalk
59 papers · 4 as a fellow
George Carrum
46 papers
Carlos Ramos
36 papers · 1 as a fellow
Caridad Martinez
27 papers · 1 as a fellow
Premal Lulla
25 papers
KL
Kathryn Leung
22 papers
Nabil Ahmed
21 papers
RK
Rammurti Kamble
20 papers
Swati Naik
17 papers
Robert Krance
16 papers

Grants

BMT CTN Core: Baylor College of Medicine Consortium
National Heart, Lung, and Blood Institute · UG1
Contact PI · $2.1M · Baylor College of Medicine
2011–2031
Baylor College of Medicine Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $10.3M · Baylor College of Medicine
2007–2030
Training In Cell and Gene Therapy
National Heart, Lung, and Blood Institute · T32
Contact PI · $6.9M · Baylor College of Medicine
2003–2028
SPORE in Lymphoma
National Cancer Institute · P50
Contact PI · $48.2M · Baylor College of Medicine
2007–2027

Clinical trials

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Principal investigator · Not yet recruiting · Phase 1
The Methodist Hospital Research Institute
2027–2044
5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)
Principal investigator · Withdrawn · Early phase 1
Baylor College of Medicine
2025–2029
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Principal investigator · Active not recruiting · Phase 1
Tessa Therapeutics
2022–2037
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Principal investigator · Active not recruiting · Phase 2
Tessa Therapeutics
2021–2037